All In MedTech

FDA Clearance Tracker · P210019-S002

ADVIA Centaur Anti-HBc Total (HBcT2) and Atellica IM Anti-HBc Total (HBcT2)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 28, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 28, 2023

Approved

Time to decision

179 days

Received Oct 31, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class II

The decision

FDA number
P210019-S002
Device name
ADVIA Centaur Anti-HBc Total (HBcT2) and Atellica IM Anti-HBc Total (HBcT2)
Applicant location
Tarrytown, NY
Received
Oct 31, 2022
Decided
Apr 28, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P210019

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

Approve inclusion of pediatric subjects in the intended use population for the ADVIA Centaur XP/XPT, ADVIA Centaur CP, and Atellica IM Analyzers

Source documents

Other decisions for Siemens Healthcare Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.